262 related articles for article (PubMed ID: 8935261)
1. Immunogenicity and reactogenicity of indigenously produced MMR vaccine.
Bhargava I; Chhaparwal BC; Phadke MA; Irani SF; Chhaparwal D; Dhorje S; Maheshwari CP
Indian Pediatr; 1995 Sep; 32(9):983-8. PubMed ID: 8935261
[TBL] [Abstract][Full Text] [Related]
2. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
[TBL] [Abstract][Full Text] [Related]
3. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
4. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
Gerike E; Tischer A
Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
[TBL] [Abstract][Full Text] [Related]
5. [Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella].
Just M; Berger R; Glück R; Wegmann A
Schweiz Med Wochenschr; 1985 Nov; 115(48):1727-30. PubMed ID: 4081704
[TBL] [Abstract][Full Text] [Related]
6. [Clinico-immunologic evaluation of a trivalent vaccine against measles, rubella and mumps].
Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
Minerva Pediatr; 1989 Mar; 41(3):117-22. PubMed ID: 2747598
[TBL] [Abstract][Full Text] [Related]
7. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
[TBL] [Abstract][Full Text] [Related]
8. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan.
Chiu HH; Lee CY; Chih TW; Lee PI; Chang LY; Lin YJ; Hsu CM; Huang LM
J Med Virol; 1997 Jan; 51(1):32-5. PubMed ID: 8986946
[TBL] [Abstract][Full Text] [Related]
9. The immunogenicity and reactogenicity of the trivalent vaccine, Trimovax, indicated for prevention of measles, mumps, and rubella, in 12-month-old children in Belarus.
Samoilovich EO; Kapustik LA; Feldman EV; Yermolovich MA; Svirchevskaya AJ; Zakharenko DF; Fletcher MA; Titov LP
Cent Eur J Public Health; 2000 Aug; 8(3):160-3. PubMed ID: 10965439
[TBL] [Abstract][Full Text] [Related]
10. Combination measles, mumps, rubella and varicella vaccine.
Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
Sultana R; Rahman MM; Hassan Z; Hassan MS
Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
[TBL] [Abstract][Full Text] [Related]
12. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
13. Serological evaluation of 52 children immunized with the combined measles, mumps and rubella vaccine.
Topal B; Kanra G; Ceyhan M
Turk J Pediatr; 1991; 33(1):13-8. PubMed ID: 1844171
[TBL] [Abstract][Full Text] [Related]
14. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
[TBL] [Abstract][Full Text] [Related]
15. [A seroconversion study of the measles component of the MMR vaccine in adolescents of the town of Sabrosa].
Gonçalves G; Tavares F; de Andrade HR
Acta Med Port; 1998 Dec; 11(12):1079-84. PubMed ID: 10192981
[TBL] [Abstract][Full Text] [Related]
16. Response to measles-mumps-rubella vaccine in children on dialysis.
Schulman SL; Deforest A; Kaiser BA; Polinsky MS; Baluarte HJ
Pediatr Nephrol; 1992 Mar; 6(2):187-9. PubMed ID: 1571219
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and efficacy of Hoshino strain of mumps vaccine in Iran; two years study.
Avijgan M; Hafizi M; Moghni M; Kheiri S; Esteghamati A; Sarikhani S
East Afr J Public Health; 2011 Jun; 8(2):88-91. PubMed ID: 22066292
[TBL] [Abstract][Full Text] [Related]
18. [Sero-epidemiologic study of measles, rubella and mumps in the infantile population of Salamanca].
Sáenz González MC; Núñez Mateos JC; Rodrigo Sánchez N; Martín Sánchez AM
An Esp Pediatr; 1992 Apr; 36(4):293-7. PubMed ID: 1605414
[TBL] [Abstract][Full Text] [Related]
19. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
Usonis V; Bakasenas V; Kaufhold A; Chitour K; Clemens R
Pediatr Infect Dis J; 1999 Jan; 18(1):42-8. PubMed ID: 9951979
[TBL] [Abstract][Full Text] [Related]
20. [Duration of immunity and occurrence of secondary vaccine failure following vaccination against measles, mumps and rubella].
Trier H; Rønne T
Ugeskr Laeger; 1992 Jul; 154(29):2008-13. PubMed ID: 1509566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
